Can "Ultra-low" dose Rituximab work for RA?
At day 3 of ACR Convergence 2021, the REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid art
At day 3 of ACR Convergence 2021, the REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid art
My favorite three presentations from day 4 at ACR 2021 included the following:
Breakthrough Infections in Rheumatic Disease Patients
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites:
Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis.
The third day of ACR 2021 took a big leap in online content. Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
The COVID-19 pandemic has presented a global challenge. Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections.
CreakyJoints will present 11 posters and two oral presentations at ACR 2021. Data was derived from their large patient database and Arthritis Power Research Registry. COVID-19 research revealed significantly high levels of anxiety, anger, depression, and social isolation, which we
Post-pandemic structured surveys and interviews with rheumatology patients suggests they may prefer for face-to-face consultations, as telehealth visits run the risk of diagnostic inaccuracies and safety concerns.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a t
Dr. Jack Cush reviews the news and journal articles from the past week and discusses parent-child rheumatologists pairs.
Leonard Calabrese @LCalabreseDO ( View Tweet )
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Eric Topol @EricTopol ( View Tweet )